Multispecific antigen-binding molecules and uses thereof

US11191844B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Julian Andreev · Sleepy Hollow, US
• Nithya Thambi · Furlong, US
• Frank Delfino · Poughquag, US
• Joel H. Martin · Putnam Valley, US
• Gavin Thurston · Briarcliff Manor, US
• Katherine Cygnar · New York, US
• Nicholas J. Papadopoulos · Lagrangeville, US

Key dates

• Filing date: Jul 6, 2016
• Grant date: Dec 7, 2021
• Expiry date: Sep 21, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the disclosure, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure causes or facilitates the targeted killing of tumor cells.